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Abstract 
Review on SPARC, with data on DNA, on the 
protein encoded, and where the gene is implicated. 
Keywords 
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Osteoporosis; Pulmonary Fibrosis Cardiac Fibrosis; 
Breast cancer. 
Identity 
Other names: BM-40; ON, OI17 
HGNC (Hugo): SPARC 
Location: 5q31.3-q32 
Location (base pair) 
Start: 151,661,096bp from pter End: 151,687,165bp 
from pter (GRCh38.5 - 22/09/2015); Size: 26,070 
bases; Orientation: Minus strand 
DNA/RNA 
Description 
DNA size:  26,070 kb; Exon count: 10; mRNA size: 
3604 bp NM_003118. A CPG-rich sequence has 
been identified at the 5' region of the SPARC gene, 
characterizing the presence of CpG island spanning 
from exon 1 to intron 1 (Yang et al., 2007). 
Transcription 
Three transcript variants encoding different 
isoforms have been found for this gene.  
NM_003118.3 - Homo sapiens secreted protein 
acidic and cysteine-rich (SPARC), transcript variant 
1, mRNA: NP_003109.1. Transcript size: 3604 bp. 
Variant 1 encodes the predominant isoform.  
NM_001309443.1 - Homo sapiens secreted protein 
acidic and cysteine-rich (SPARC), transcript variant 
2, mRNA: NP_001296372.1. Transcript size: 3601 
bp. Variant 2 uses an alternate in-frame splice 
junction at the 5' end of an exon compared to 
variant 1. The resulting isoform has the same N- 
and C-termini but is 1 aa shorter compared to 
isoform 1. NM_001309444.1  -  Homo sapiens 
secreted protein acidic and cysteine-rich (SPARC), 
transcript variant 3, mRNA: NP_001296373.1 . 
Transcript size: 3602 bp. Variant 3 uses an alternate 
splice junction at the 5' end of the last exon 
compared to variant 1 that causes a frameshift. The 
resulting isoform has a longer and distinct C-
terminus compared to isoform 1. 
Protein 
Note 
SPARC encodes a cysteine-rich acidic matrix-
associated protein that belongs to a family of 
SPARC-related proteins composed of others six 
members, that include SPOCK1, SPOCK2, 
SPOCK3, SPARCL1, SMOC1, SMOC2 (testican-1, 
-2, -3, SPARC-like 1 (or hevin, Mast9), and 
SPARC-related modular calcium binding (SMOC)-
1, and -2). All members of this protein family share 
the three similar domains (Bradshaw and Sage, 
2001; Brekken and Sage, 2000). SPARC protein is 
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required for the collagen in the bone to become 
calcified. SPARC is also involved in extracellular 
matrix synthesis and remodeling being associated 
with the promotion of changes in cell shape. 
SPARC protein has been associated with tumor 
suppression but has also been correlated with 
metastasis based on changes to cell shape which 
can promote tumor cell invasion (GeneCard 
RefSeq). Molecular weight: 303aa, 43 kDa; 
Isoelectric point: 4.4719. Although, after cleavage 
of the signal sequence, SPARC is a 32-kDa protein 
(Mason et al. 1986), the secreted form is identified 
as a 43 kDa protein on SDS-PAGE, which is due to 
the addition of carbohydrate (Sage et al. 1984). 
NP_003109.1: molecular weight: 303 aa; 
NP_001296372.1: molecular weight: 302 aa; 
NP_001296373.1: molecular weight: 341 aa 
Description 
SPARC is a 43kDa protein, composed of 303 
aminoacids. The first 17 amino acids containing the 
signaling peptide sequence is removed during 
protein processing. SPARC protein has three 
structural domains: N-terminal domain (NT; aa 3-
51) encoded by exons 3 and 4, follistatin-like
domain (FS; 53-137 aa) encoded by exons 5 and 6, 
the Extra Cellular domain (EC; aa 138-286) 
encoded by exons 7 to 9. It has eleven collagen- and 
six high-affinity Ca2+ binding residues. Also, the 
protein presents cleavage sites for cathepsin and 
members of the metalloproteinases family (Brekken 
and Sage, 2000; figure 1). The NT domain binds 
hydroxyapatite and calcium ions. The FS domain 
contains several internal disulfide bonds that 
stabilize two weakly interacting modules. The N-
terminus region of the FS domain has a very 
twisted-hairpin structure that is linked by disulfide 
bonds at cysteines 1-3, and 2-4. This distribution of 
disulfide bonds makes the FS-domain structurally 
homologous to epidermal growth factor (EGF)-like 
domain of factor IX, a coagulation factor. At the 
other end of the FS-domain, its C-terminus region 
has structural similarity to Kazal family of serine 
proteases. It has antiparallel alpha-helices 
connected to small three-stranded antiparallel 
alpha-sheets with disulfide bonds linking cysteines 
5-9, 6-8, 7-10. The EC domain contains two E-F 
hand motifs that bind calcium with high affinity, 
and comprise almost entirely of alpha-helices 
(Hohenester et al., 1997). 
Expression 
The evaluation of the expression pattern of SPARC 
protein and mRNA during human embryonic and 
fetal development revealed that it is usually 
expressed in tissues undergoing rapid proliferation 
(Mundlos et al., 1992). These authors also showed 
that earlier developmental stages showed a more 
general distribution, changing to more 
heterogeneity expression pattern in later stages. 
SPARC expression was observed in bone, cartilage, 
teeth, kidney, gonads, adrenal gland, lung, eye, 
vessels (Mundlos et al., 1992). In adults SPARC is 
expressed in different tissues and organs, including 
bone marrow, whole blood, lymph node, thymus, 
brain, cerebellum, retina, heart, smooth muscle, 
skeletal muscle, spinal cord, intestine, colon, 
adipocyte, kidney, liver, pancreas, thyroid, salivary 
gland, skin, ovary, uterus, placenta, cervix and 
prostate (Wang et al, 2014). 
Figure 1 - Schematic representation of the 303 aa human SPARC protein with its functional and structural domains.  Box 
represents the three functional domains: acidic domain (18-52aa), follistatin-like (53-137aa), extracellular Ca2+-binding (138- 
286aa). The first seventeen amino acids correspond to the signaling peptide. Stars and triangles represent some of the structural 
domains: yellow and green stars represent collagen-binding and high-affinity Ca2+-binding residues, respectively. Triangles 
represent cleavage sites for cathepsin (blue), MMP2, MMP3, MMP7, MMP9, and MMP13 (red), and MMP3 (purple). (based on 
Brekken and Sage, 2001; Chlenski and Cohn, 2010) 
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It is also described that SPARC is expressed by 
different cell types including active osteoblasts, 
bone marrow progenitor cells, odontoblasts 
endothelial cells, fibroblasts, pericytes, astrocytes 
and macrophages (McCurdy et al. 2010; Rosseta 
and Bradshaw, 2016). In cancer, according to 
PrognoScan database, SPARC expression was 
observed in bladder, blood, brain, breast, colorectal, 
eye tumors, glioma, head and neck cancer, lung, 
esophagus, ovarian, and skin cancer tissues (Wang 
et al., 2014). There are evidences that SPARC 
expression is transcriptionally regulated by 
methylation in different types of neoplasia such as 
ovarian cancer (Socha et al, 2009), pancreatic 
cancer (Vaz et al, 2015), hepatocellular carcinoma 
(Zhang et al, 2012) colorectal (Cheetham et al., 
2008) and breast (Matteucci et al, 2016). Loss of 
heterozygosity (LOH) at 5q has been demonstrated 
in pancreatic cancer (Hahn et al., 1995), in 
pulmonary fibrosis (Demopoulos et al., 2002) and 
myelodysplastic syndromes (Giagounidis et al., 
2014). 
Localisation 
SPARC is a secreted glycoprotein found mainly in 
the extracellular compartment.  
However, it has also been described to be localized 
both to cell nucleus and to cytoplasm (Hudson et 
al., 2005; Baldini et al. 2008). 
Function 
SPARC is an evolutionarily conserved matricellular 
glycoprotein that is involved in diverse biological 
processes, including tissue remodeling, wound 
repair, morphogenesis, cell differentiation, 
proliferation, migration, and angiogenesis. 
Matricellular glycoprotein proteins are a family of 
proteins that can be associated with structural 
elements and mediates cell-matrix interaction rather 
than functions as extracellular matrix (ECM) 
structural elements (Bornstein, 1995). 
SPARC was first described in skeletal tissue as a 
bone-specific protein that binds selectively to both 
hydroxyapatite and collagen (Termine et al., 1981). 
Posteriorly, it was shown that this protein is broadly 
expressed both in mineralized and non-mineralized 
tissues being associated to ECM, regulating cell-
matrix interactions and cellular functions, than 
contributing to ECM organization (Bornstein, 2000; 
Bradshaw, 2012). 
SPARC has also been shown to regulate the activity 
of matrix metalloproteinases (MMP), a family of 
enzymes capable of breaking down proteins, such 
as collagen, normally found in ECM and considered 
to be the mediators of ECM proteolysis and 
turnover. Angiogenesis, healing and metastasis, 
processes that require ECM restructuring are 
associated with higher SPARC production. 
The influence of SPARC on MMP-1, MMP-3, and 
MMP-9 activity was first described by Tremble et 
al., 1993. Further studies were carried out in 
transformed cells and tumor, and it was 
demonstrated that SPARC could increase MMP-2 
activity in glioma cells and breast cancer cells but 
not in melanoma cells (McClung et al., 2007, 
Nischt et al., 2001, Gilles et al., 1998). 
Homology 
The human SPARC gene shows 92% and 31% 
identity with the mouse and nematode homologs, 
respectively. SPARC is conserved in a wide variety 
of evolutionarily diverse organisms (e.g., C. 
elegans, Drosophila, brine shrimp, trout, chicken, 
mice, and humans), suggesting that it plays an 
important function in multicellular biology 
(Bradshaw and Sage, 2001). 
Implicated in 
Osteogenesis Imperfecta, Type XVII 
SPARC gene mutations have been correlated with a 
severe disease known as osteogenesis imperfecta, a 
connective tissue disorder characterized by low 
bone mass, bone fragility and susceptibility to 
fractures after minimal trauma. Whole-exome 
sequencing was carried out in 2 unrelated girls 
carrying osteogenesis imperfecta (OI17; 616507) 
leading to the identification of two different 
homozygous missense mutations, R166H 
(VAR_075142) and E263K (VAR_075143) 
(Mendoza-Londono et al., 2015). Previous studies 
described diminished expression of SPARC in  
osteoblasts from patients with osteogenesis 
imperfecta (Muriel et al., 1991) and in osteoblasts 
obtained from the fro/fro mouse, an animal with 
fragile bones (Vetter et al., 1991) 
Osteoporosis 
The involvement of SPARC in bone remodeling 
has been described, and its expression is observed 
in osteoblasts express (Kelm et al., 1992). SPARC-
null mice were reported to have decreased numbers 
of osteoblasts and osteoclasts, indicating decreased 
bone turnover, resulting in low turnover 
osteoporosis-like phenotype affecting trabecular 
bone (Delany, et al., 2000). Also, in osteonectin-
null mice, osteonectin levels have been shown to 
play a role in modulating the balance of bone 
formation and resorption in response to PTH 
treatment (Machado do Reis et al., 2008). 
Pulmonary and Cardiac Fibrosis 
Fibrosis is characterized by excessive deposition of 
extracellular matrix, resulting in tissue remodeling 
and thus interfering with normal tissue architecture 
and function.  
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SPARC expression and up-regulation have been 
reported in multiple types of fibrosis both human 
and animal fibrotic models. It has been shown that 
SPARC can influence TGFB1 (TGF-beta), a known 
regulator of fibrosis. Thus it is suggested that 
SPARC may regulate TGF-beta activity in fibrotic 
tissues (Trombetta and Bradshaw, 2012). 
Cardiac disease 
SPARC expression was reported in cardiac disease. 
It is highly expressed in fibroblasts and endothelial 
cells and less expressed in cardiac myocytes. By 
screening analysis, SPARC was found as 
differentially expressed and potentially associated 
with myocardial infarction and transverse aortic 
constriction (Wang et al., 2015). Also, SPARC 
demonstrated to have potential therapeutic 
applications in inhibiting cardiac dilatation and 
dysfunction after myocardial infarction (Schelling 
et al., 2009). 
Cancer 
SPARC protein modulates different cell functions 
like as adhesion, proliferation, angiogenesis, cell 
survival, and has been associated with tumor 
development and progression (Arnold and Brekken, 
2009; Nagaraju et al., 2014).  
SPARC is differentially expressed in different types 
of cancer, and its ability to inhibit or promote tumor 
progression is dependent on the cellular type, 
tumoral stage and the type of established 
interactions among the different components of 
cellular microenvironment (Arnold and Brekken, 
2009).  
The pleiotropic effects of SPARC reflect the 
complexity of actions of this protein, which can act 
as an oncogene or tumor suppressor (Podhajcer et 
al.,2008; Arnold and Brekken, 2009). Hence, the 
role of SPARC in the process of tumorigenesis and 
as a tumor biomarker is still controversial. Higher 
levels of SPARC were observed in  malignant 
tumors, including breast, esophagus, brain, prostate, 
glioma, and melanoma, suggesting that increased 
SPARC expression is associated with tumor 
progression (Framson and Sage, 2004; Bos et 
al.,2004; Watkins et al.,2005; Koblinski et 
al.,2005). On the other hands, other studies have 
suggested that SPARC may act as a tumor 
suppressor, promoting apoptosis in ovarian cancer 
cells and presenting an anti-tumoral effect in 
pancreatic and breast cancers (Chlenski and Cohn, 
2010; Nagai et al.,2011).  
Tumor with high metastatic potentials such as 
glioblastomas, melanoma, breast and prostate 
cancer, express higher levels of SPARC while less 
metastatic tumor-like ovarian, pancreatic and 
colorectal tumors, expresses lower or undetectable 
SPARC (Feng and Tang, 2014).  
The diversity of SPARC expression effects has 
been observed in different types of cancers. SPARC 
has been associated with tumor development in 
melanoma, esophagus cancer, gastric cancer and 
glioma, and data suggests that higher expression is 
correlated with a more aggressive phenotype such 
as tumor size, metastasis and poor prognosis 
(Yamashita K et al., 2003; Bos et al.,2004; Framson 
and Sage, 2004; Wang  et al., 2004; Koblinsk et 
al.,2005; Zhao et al., 2010; Fenouille et al., 2011; 
Liu et al., 2011; Rocco et al., 2011; McClung et al., 
2012; Kim et al., 2013) 
The expression of SPARC does not seem to directly 
influence cellular transformation since SPARC 
knockout mice do not develop tumors. However, 
SPARC might significantly influence tumor-stroma 
interactions contributing to tumor progression and 
therapy response (Said et al., 2013).  
In different tumor types such as prostatic 
carcinoma, neuroblastoma, pulmonary carcinoma, 
leukemia, pancreatic and colorectal cancer, it was 
described that SPARC inhibits tumor growth and 
reverts drug resistance increasing chemotherapy 
response. (Brekken et al., 2003; Sato et al., 2003; 
Puolakkainen et al., 2004; Said and Motamed, 
2005; Tai et al., 2005; DiMartino et al., 2006; Tai 
and Tang, 2007; Cheetam et al., 2008; Pan et al., 
2008; Wong et al., 2008; Socha et al., 2009; 
Bhoopathi et al., 2011; Davids and Steensma, 2010; 
Chew et al., 2011; Rahman et al., 2011).  
Cheetham et al., 2008, showed that the 
demethylating agent 5-Aza-2'deoxycytidine (5-Aza) 
leads to the expression of SPARC and increased 
chemosensitivity in colon cancer cells. In 
irinotecan-resistant cancer cells, endogenous or 
exogenous SPARC exposure triggers senescence 
associated with increased levels of p16 and TP53 
phosphorylation (Chan et al., 2010).  Also, in vitro 
and in vivo studies have demonstrated that over-
expression of the NT-domain of SPARC leads to a 
significantly greater sensitivity to chemotherapy 
and tumor regression that involves an interplay 
between the NT-domain, BCL2 and CASP8 
(caspase 8), which increases apoptosis and confers 
greater chemosensitivity (Rahman et al., 2011). 
More recently, Fan et al., demonstrated that over-
expression of SPARC increased gemcitabine-
induced apoptosis in pancreatic cancer cells via up-
regulation of the expression of apoptosis-related 
proteins. These findings provide insight on the role 
played by SPARC in drug sensitivity and that its re-
expression has a potential to restore 
chemosensitivity. 
Breast cancer 
In breast cancer, SPARC is expressed in more 
invasive but not in non-invasive cell lines (Giles et 
al., 1998).  
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In normal mammary tissue, SPARC expression was 
undetectable or slightly detectable and in benign 
mammary lesions the expression was weakly 
positive. However, the stromal cell of 75% of in 
situ and invasive breast cancer samples was 
strongly positive for SPARC (Bellahcène and 
Castronovo, 1995; Barth et al., 2005; Matteucci et 
al., 2016).  
As previous described, the role of SPARC in breast 
cancer is also controversial.  SPARC expression is 
not detected in MCF-7 breast cancer cell line, 
however, in response to c-Jun overexpression, 
SPARC expression is highly induced being 
associated to increased invasive and migration 
potential (Briggs et al., 2002). Instead, in the 
tumorigenic model of breast cancer cells, MDA-
MD-231, SPARC expression inhibited invasion and 
metastasis (Koblinski et al., 2005).  
In breast tumors increased SPARC expression was 
associated with tumor progression and 
aggressiveness phenotype (Watkins et al., 2005 and 
Helleman et al. 2008). On the other hand, the 
reduction of SPARC protein expression was 
associated with poor prognosis of breast cancer 
patients (Hsiao et al., 2010 e Nagai et al., 2011). In 
breast cancer brain metastasis SPARC expression 
was down-regulated in comparison to primary 
tumors, apart from the tumoral subtype. However, 
among the primary tumors evaluated, triple 
negative subtype expressed the higher protein level 
(Wikman et al., 2014). Previous data of our group, 
have already shown that association between 
SPARC and triple negative tumors, and positivity to 
SPARC was a marker of good prognosis in 
comparison to those patients with reduced SPARC 
level (Nagai et al., 2011). 
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